Lipid Panel Reference Chart

Comprehensive Clinical Interpretations and Risk Stratification

Component Age Group Reference Range Clinical Notes
Total Cholesterol
mg/dL		 Adults (≥19 years) <200
Desirable: <200 mg/dL
Borderline High: 200-239 mg/dL
High: ≥240 mg/dL
Total cholesterol alone is insufficient for cardiovascular risk assessment. HDL and LDL components provide better clinical insight.
Children/Adolescents (0-18 years) <170
HDL Cholesterol
mg/dL		 Males >40
Low (increased risk): Men <40, Women <50
High (protective): ≥60 mg/dL
Clinical Pearl: HDL ≥60 mg/dL is considered a negative risk factor that removes one risk factor from the total count
Exercise, moderate alcohol consumption, and weight loss can increase HDL levels. Smoking cessation prevents HDL reduction.
Females >50
LDL Cholesterol (Calculated)
mg/dL		 Adults <130
Optimal: <100 mg/dL
Near Optimal: 100-129 mg/dL
Borderline High: 130-159 mg/dL
High: 160-189 mg/dL
Very High: ≥190 mg/dL
Friedewald Equation: LDL = Total Cholesterol - HDL - (Triglycerides ÷ 5)
Important: Calculated LDL becomes unreliable when triglycerides >400 mg/dL. Direct LDL measurement (DLDL) recommended above this threshold.
Primary target for therapy. Goals vary by cardiovascular risk: Very high risk <70, High risk <100, Moderate risk <130
Direct LDL (DLDL)
mg/dL		 Adults <130
Method: Spectrophotometry
When to Order: Triglycerides >400 mg/dL, or by provider request
CPT Code: 83721
Specimen: Gold (SST) tube or lithium heparinized plasma
Stability: 5 days refrigerated
More accurate than calculated LDL when triglycerides are elevated. May be reflexively ordered by laboratory when TG >400 mg/dL.
Triglycerides
mg/dL		 Adults 30-149
Normal: <150 mg/dL
Borderline High: 150-199 mg/dL
High: 200-499 mg/dL
Very High: ≥500 mg/dL
Requires 9-12 hour fast. Associated with metabolic syndrome, diabetes, and pancreatitis risk when very high (≥500 mg/dL).
Non-HDL Cholesterol
mg/dL		 Adults <160
Formula: Total Cholesterol - HDL Cholesterol
Target by Risk:
• Very High Risk: <100 mg/dL
• High Risk: <130 mg/dL
• Moderate Risk: <160 mg/dL
Useful when triglycerides ≥200 mg/dL make LDL calculation less reliable. Secondary target after LDL goal achieved.

NCEP ATP III Risk Categories and LDL Goals

Risk Category LDL Goal (mg/dL) Consider Drug Therapy Patient Characteristics
Very High Risk <70 ≥70 Established CHD + diabetes, acute coronary syndrome, multiple major risk factors
High Risk <100 ≥100 CHD or CHD equivalent (diabetes, peripheral arterial disease)
Moderate Risk <130 ≥130 2+ risk factors, 10-year risk 10-20%
Lower Risk <160 ≥190 0-1 risk factors

Major Risk Factors for CHD (NCEP ATP III)

Positive Risk Factors

  • Age: Men ≥45 years, Women ≥55 years
  • Family history of premature CHD
  • Cigarette smoking
  • Hypertension (≥140/90 or on antihypertensive medication)
  • Low HDL cholesterol (<40 mg/dL)

Negative Risk Factor

  • High HDL cholesterol (≥60 mg/dL)
If HDL ≥60 mg/dL, subtract 1 from total risk factor count

ATP III Stepwise Risk Assessment and Treatment Algorithm

Step 1: Obtain Lipid Profile

Complete lipoprotein profile after 9-12 hour fast

  • Total cholesterol
  • LDL cholesterol (calculated or direct)
  • HDL cholesterol
  • Triglycerides

Step 2: Identify CHD Risk Equivalents

  • Clinical CHD
  • Diabetes mellitus
  • Symptomatic carotid artery disease
  • Peripheral arterial disease
  • Abdominal aortic aneurysm

Step 3: Count Major Risk Factors

  • Age: Men ≥45, Women ≥55 years
  • Family history of premature CHD
  • Cigarette smoking
  • Hypertension (≥140/90 or on medication)
  • Low HDL (<40 mg/dL)
Note: HDL ≥60 mg/dL removes one risk factor

LDL Goals and Treatment Thresholds by Risk Category

Risk Category LDL Goal Start TLC Consider Drug Therapy
CHD or CHD Risk Equivalent
(10-year risk >20%)		 <100 mg/dL ≥100 mg/dL ≥130 mg/dL
(100-129: optional)
2+ Risk Factors
(10-year risk <20%)		 <130 mg/dL ≥130 mg/dL 10-20% risk: ≥130 mg/dL
<10% risk: ≥160 mg/dL
0-1 Risk Factor <160 mg/dL ≥160 mg/dL ≥190 mg/dL
(160-189: optional)

Therapeutic Lifestyle Changes (TLC) Components

TLC Diet:
  • Saturated fat <7% of total calories
  • Dietary cholesterol <200 mg/day
  • Consider viscous fiber (10-25 g/day)
  • Plant stanols/sterols (2 g/day) as therapeutic option
Additional Components:
  • Weight management
  • Increased physical activity

Drug Therapy Options (ATP III)

Drug Class LDL Reduction HDL Effect TG Effect Major Side Effects
HMG-CoA reductase inhibitors (statins) 18-55% ↑5-15% ↓7-30% Myopathy, increased liver enzymes
Bile acid sequestrants 15-30% ↑3-5% No change/increase GI distress, constipation
Nicotinic acid 5-25% ↑15-35% ↓20-50% Flushing, hyperglycemia, hepatotoxicity
Fibric acids 5-20% ↑10-20% ↓20-50% Dyspepsia, gallstones, myopathy

Metabolic Syndrome Criteria (NCEP ATP III)

Diagnosis requires 3 or more of the following:

Component Men Women
Waist Circumference >102 cm (40 in) >88 cm (35 in)
Triglycerides ≥150 mg/dL
HDL Cholesterol <40 mg/dL <50 mg/dL
Blood Pressure ≥130/85 mmHg or on medication
Fasting Glucose ≥100 mg/dL or on medication

Alternative Guideline Perspectives: ATP III vs. 2018 ACC/AHA

Clinical Context: While ATP III is widely used in psychiatric metabolic monitoring, clinicians may also consider the 2018 ACC/AHA guidelines for primary cardiovascular prevention.
Current Chart Emphasis: This tool primarily follows ATP III guidelines (2001), which remain widely used for risk stratification and LDL goal setting.
Alternative Approach: The 2018 ACC/AHA guidelines emphasize cardiovascular risk assessment using pooled cohort equations and focus on statin intensity rather than specific LDL targets. Consider consulting both approaches for comprehensive cardiovascular risk management.
Aspect ATP III (2001) 2018 ACC/AHA
Primary Focus LDL cholesterol targets Statin intensity and cardiovascular risk reduction
Risk Assessment Framingham Risk Score Pooled Cohort Equations
Treatment Approach Treat to target LDL goals Fixed-dose statin therapy based on risk
Clinical Utility Excellent for goal-setting and monitoring Simplified prescribing decisions

Clinical Pearls for Lipid Interpretation

Fasting Requirements: Total cholesterol and HDL can be measured non-fasting. Triglycerides and calculated LDL require 9-12 hour fast for accuracy.
LDL Calculation Validity: Friedewald equation (LDL = Total Chol - HDL - TG/5) is inaccurate when triglycerides >400 mg/dL. Consider direct LDL measurement.

Secondary Causes of Dyslipidemia

Elevated LDL/Total Cholesterol

  • Hypothyroidism
  • Nephrotic syndrome
  • Obstructive liver disease
  • Medications: Thiazides, beta-blockers, oral contraceptives

Low HDL Cholesterol

  • Smoking
  • Obesity
  • Physical inactivity
  • Type 2 diabetes
  • Medications: Beta-blockers, anabolic steroids

Elevated Triglycerides

  • Diabetes mellitus
  • Obesity
  • Alcohol excess
  • Hypothyroidism
  • Kidney disease
  • Medications: Estrogens, corticosteroids, HIV protease inhibitors

🚨 Critical Clinical Flags

  • Triglycerides ≥500 mg/dL: Risk of acute pancreatitis - consider immediate therapy
  • LDL ≥190 mg/dL: Suggests familial hypercholesterolemia - family screening indicated
  • HDL <20 mg/dL: Investigate secondary causes and genetic disorders
  • Total cholesterol <120 mg/dL: May indicate malnutrition, liver disease, or hyperthyroidism

🧠 Psychiatric Medications and Lipid Effects

Many psychiatric medications significantly impact lipid metabolism. Regular monitoring enables early intervention and improved cardiovascular outcomes in patients with mental health conditions.

High Risk Medications

High Risk (RED):
  • Clozapine: Significant ↑ triglycerides, ↑ total cholesterol
  • Olanzapine: ↑ triglycerides, ↑ LDL, ↓ HDL
  • Quetiapine: ↑ triglycerides, variable cholesterol effects
  • Risperidone: Moderate ↑ triglycerides
Monitoring: Baseline, 12 weeks, then annually minimum

Moderate Risk Medications

Moderate Risk (ORANGE):
  • Lithium: May ↑ triglycerides and cholesterol
  • Valproate: ↑ triglycerides, weight gain-related effects
Some Antidepressants (ORANGE):
  • Mirtazapine: ↑ triglycerides, ↑ cholesterol
  • TCAs: Variable effects, often weight-related

Lower Risk Medications

Lower Risk (GREEN):
  • Haloperidol: Minimal direct lipid effects
  • Fluphenazine: Generally neutral
Most Antidepressants (GREEN):
  • SSRIs: Generally neutral or beneficial
  • SNRIs: Minimal effects
  • Bupropion: May improve lipid profile

Clinical Management Strategies

  • Pre-treatment screening: Baseline lipid panel before starting high-risk medications
  • Regular monitoring: 12 weeks, 6 months, then annually for high-risk agents
  • Lifestyle interventions: Diet, exercise, smoking cessation counseling
  • Medication adjustment: Consider switching if significant dyslipidemia develops
  • Cardiology consultation: For complex cases or multiple cardiovascular risk factors

APA/ADA Consensus Guidelines for Metabolic Monitoring

Adult Monitoring Schedule
Parameter Baseline 12 Weeks Annually
Lipid Panel ✓ ✓ ✓
Weight/BMI ✓ ✓ ✓
Glucose/A1C ✓ ✓ ✓
Blood Pressure ✓ ✓ ✓
Pediatric Monitoring Schedule
Parameter Baseline 3 Months Every 6 Months
Lipid Panel ✓ ✓ ✓
Glucose Assessment ✓ ✓ ✓
Weight/BMI/Growth ✓ ✓ ✓
Blood Pressure ✓ ✓ ✓

🧒 Pediatric-Specific Monitoring Guidelines

Superior HealthPlan Medicaid/CHIP Requirements (2019):

  • Fasting glucose and lipid monitoring required every 6 months for youth on antipsychotics
  • Order one lab from each column: Glucose assessment (Basic/Comprehensive Metabolic Panel, A1C, or Glucose) AND Lipid assessment (Lipid Panel, Total Cholesterol, or individual components)
  • Youth may require more frequent monitoring than adults due to rapid growth and development
  • Consider point-of-care monitoring to reduce barriers to testing
Medicaid Monitoring Mandates: Providers should be aware that Medicaid plans actively monitor compliance with these guidelines and may reach out if members have not received appropriate monitoring within the required timeframe.

LDL Cholesterol Calculator (Friedewald Equation)

Formula: LDL = Total Cholesterol - HDL - (Triglycerides ÷ 5)




Note: This calculation is invalid when triglycerides >400 mg/dL. Direct LDL measurement required.

Non-HDL Cholesterol Calculator

Formula: Non-HDL = Total Cholesterol - HDL Cholesterol



Framingham Risk Score Calculator

Simplified version - Full assessment requires comprehensive evaluation






Note: This is a simplified calculator. Use validated tools for clinical decision-making.

Disclaimer:

The information provided in this Lipid Panel Reference Tool is intended solely for educational and informational purposes. It does not constitute medical advice, diagnosis, or treatment, nor does it establish a provider-patient relationship. While efforts have been made to ensure the accuracy and clinical relevance of the content, PsychConcierge PLLC and PsychConcierge.com make no warranties, express or implied, regarding the completeness, reliability, or applicability of the information presented. Users are strongly encouraged to consult their licensed healthcare provider for interpretation of laboratory values and individualized medical decisions. Reference ranges may vary by laboratory and patient population. PsychConcierge PLLC assumes no responsibility for any outcomes arising from reliance on this tool.